Last Updated : July 24, 2024
Details
Generic Name:
icatibant
Project Status:
Not filed
Therapeutic Area:
Acute attacks of hereditary angioedema
Manufacturer:
Takeda Canada Inc.
Brand Name:
Firazyr
Project Line:
Reimbursement Review
Project Number:
NS0014-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Acute attacks of hereditary angioedema in adolescents and children aged two years and older with C1-esterase inhibitor deficiency
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024